Determination of dabigatran, rivaroxaban and apixaban by ultra‐performance liquid chromatography – tandem mass spectrometry (UPLC‐MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A. (2008) · Blood · doi:10.1182/blood-2008-05-160143 · Cited by 342
Robert, S., Chatelain, C., Douxfils, J., Mullier, F., Chatelain, B., & Dogné, J.-M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0804 · Cited by 325
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Stangier, J., & Feuring, M. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834f1b0c · Cited by 265
Hawes, E. M., Deal, A. M., Funk‐Adcock, D., Gosselin, R., Jeanneret, C., Cook, A. M., Taylor, J. M., Whinna, H. C., Winkler, A. M., & Moll, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12308 · Cited by 231
Lip, G. Y. H., Diener, H.-C., Brueckmann, M., van Ryn, J., Clemens, A., & Huisman, M. V. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0718 · Cited by 218
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
Chatelain, C., Chatelain, B., Douxfils, J., Dogné, J.-M., & Mullier, F. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-12-0898 · Cited by 213
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
Wong, P. C., Pinto, D. J. P., & Zhang, D. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0551-3 · Cited by 195
Laboratory assessment of new anticoagulants
Samama, M. M., & Guinet, C. (2011) · cclm · doi:10.1515/cclm.2011.134 · Cited by 174
Freyburger, G., Macouillard, G., Labrouche, S., & Sztark, F. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.01.001 · Cited by 162
Becker, R. C., Yang, H., Barrett, Y., Mohan, P., Wang, J. J. J., Wallentin, L. C., & Alexander, J. H. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0591-8 · Cited by 148
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests
Asmis, L. M., Alberio, L., Angelillo‐Scherrer, A., Korte, W. C., Mendez, A., Reber, G., Seifert, B., Stricker, H. J., Tsakiris, D. A., & Wuillemin, W. A. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.06.031 · Cited by 145
Rohde, G. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.07.015 · Cited by 138
Liesenfeld, K., Schäfer, H. G., Trocóniz, I. F., Tillmann, C., Eriksson, B. I., & Stangier, J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02667.x · Cited by 118
Butler, J., Malan, E., Chunilal, S. D., Tran, H., & Hapgood, G. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0301 · Cited by 83
Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays
Curvers, J., van de Kerkhof, D., Stroobants, A. K., van den Dool, E. J., & Scharnhorst, V. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpqod9wfpeyy0h · Cited by 75
Delavenne, X., Moracchini, J., Laporte, S., Mismetti, P., & Basset, T. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.09.018 · Cited by 63
Mani, H., Kasper, A., & Lindhoff‐Last, E. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0907-y · Cited by 59
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
Bassand, J. (2012) · EP Europace · doi:10.1093/europace/eur263 · Cited by 46
A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors
Barrett, Y. C., Wang, Z., & Knabb, R. M. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612441859 · Cited by 39
Cited by
Gosselin, R., Adcock, D., Bates, S., Douxfils, J., Favaloro, E., Gouin-Thibault, I., Guillermo, C., Kawai, Y., Lindhoff-Last, E., & Kitchen, S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1627480 · Cited by 392
Metadata
- Authors
- Schmitz, E. M. H., Boonen, K., van den Heuvel, D. J. A., van Dongen, J. L. J., Schellings, M. W. M., Emmen, J. M. A., van der Graaf, F., Brunsveld, L., & van de Kerkhof, D.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 12
- Issue
- 10
- Pages
- 1636-1646
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W1976542477
- Cited by
- 172
- References
- 25
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.